Cancer Advisor

OneDayMD Editorial Team | Medically reviewed and updated July 2026 Quick Answer Real, registered clinical trials are testing ivermectin and mebendazole in cancer — including a Phase I/II ivermectin + checkpoint-inhibitor trial in metastatic triple-negative breast cancer (NCT05318469) and the ICONIC ivermectin + immunotherapy trial (NCT07487805). Use the searchable tool below, verify current status directly on ClinicalTrials.gov, then contact the study coordinator or ask your oncologist to help you apply. If no trial fits, ask about the expanded access / compassionate use pathway instead of self-sourcing unregulated drugs. Table of Contents Why Clinical Trials Matter for Stage 4 Patients Interactive Trial Finder Tool Current Ivermectin & Mebendazole Trial Registry (2026) How to Search ClinicalTrials.gov Yourself Understanding Eligibility Criteria Expanded Access & Compassionate Use Red Flags: Real Trials vs. Off-Label Telehealth "Protocols" ...

Published: July 2026 | Category: Health Technology & Patient Empowerment Receiving a cancer diagnosis or going through high-stakes screenings can feel overwhelming. Historically, patients relied entirely on the keen eyes of radiologists and pathologists to detect microscopic cellular changes. However, as we move through 2026, a powerful ally has fully integrated into clinical care: AI diagnostic tools in oncology . Artificial intelligence is no longer a futuristic concept confined to research labs. Today, advanced multi-modal AI algorithms work alongside oncologists to spot anomalies faster, predict treatment responses, and minimize human error. If you or a loved one are navigating cancer screenings or treatment this year, understanding how these tools work can provide immense reassurance and empower you to advocate for your health. How AI is Transforming Cancer Detection in 2026 In 2026, medical AI systems have evol...

Quick Answer The Somatic Mutation Theory (SMT) — the model that has guided oncology since the 1970s — holds that cancer starts with random DNA mutations. The 2005 Cancer Genome Atlas Project largely dismantled that idea: no "founding mutation" was ever found, and mutation patterns varied wildly between and within tumors. The Metabolic Theory of Cancer (MTOC) , developed by Dr. Thomas Seyfried at Boston College from decades of mitochondrial research (Otto Warburg, Peter Pedersen), argues that cancer originates from damaged mitochondria forcing cells into fermentation-based energy production (the Warburg effect), with nuclear mutations arising downstream as a consequence, not a cause. This reframing supports combining standard oncology with ketogenic/calorie-restricted metabolic protocols , repurposed drug combinations (e.g., metformin, statins, mebendazole, doxycycline), and cancer-stem-cell-targeting agents — approaches now backed by published trials such as CUSP9...

Executive Summary : As nutritional oncology shifts focus from isolated "superfoods" to systemic metabolic frameworks, this comprehensive briefing reviews the current clinical consensus, structural dietary guidelines, and the rising counter-culture of repurposed therapies in 2026. 1. The Shift in Nutritional Oncology: Systems Over Components In 2026, the intersection of oncology and nutritional science has definitively moved away from reductive "magic bullet" nutrients. Following the latest updates to global dietary guidelines, the clinical community emphasizes systemic dietary architecture. Rather than evaluating isolated antioxidants, researchers are tracking how complete dietary patterns modulate systemic inflammation, insulin-like growth factors (IGF-1), and the gut microbiome to alter the host environment's receptivity to oncogenesis.  Source: American Institute for Cancer Research ...